UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
FORM 8-K
 
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934
 
Date of Report (Date of earliest event reported): March 12, 2020
 
FOAMIX PHARMACEUTICALS LTD.
(Exact name of registrant as specified in its charter)
 
Israel
001-36621
N/A
(State or other jurisdiction of incorporation)
(Commission File Number)
(IRS Employer Identification No.)

 
2 Holzman Street,
Weizmann Science Park
 
 
 
Rehovot, Israel
7670402
 
 
(Address of principal executive offices)
(Zip Code)
 
 
+972-8-9316233
(Registrant’s telephone number, including area code)
(Former name or former address, if changed since last report)
 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
 
☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
 
Securities registered pursuant to Section 12(b) of the Act:

Title of each class
Ticker symbol(s)
Name of each exchange on which registered
Ordinary Shares, par value NIS 0.16 per share
FOMX
Nasdaq Global Stock Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐
 
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ☐


Item 2.02. Results of Operations and Financial Condition.
 
On March 12, 2020, Menlo Therapeutics Inc. (“Menlo”) issued a press release announcing the financial results for the year ended December 31, 2019 for its wholly-owned subsidiary, Foamix Pharmaceuticals Ltd. (the “Company”). A copy of the press release is furnished as Exhibit 99.1 hereto.

The information in this Item 2.02 and Exhibit 99.1 hereto is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liability of that section, nor shall they be deemed incorporated by reference in any of the Company’s filings under the Securities Act of 1933, as amended (the “Securities Act”), or the Exchange Act, except as expressly set forth by specific reference in such filing.

Item 7.01 Regulation FD Disclosure
 
On March 12, 2020, Menlo issued a press release announcing the financial results for the year ended December 31, 2019 for the Company. A copy of the press release is furnished as Exhibit 99.1 hereto.
 
The information in this Item 7.01 and Exhibit 99.1 hereto is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Exchange Act, or otherwise subject to the liability of that section, nor shall they be deemed incorporated by reference in any of the Company’s filings under the Securities Act or the Exchange Act, except as expressly set forth by specific reference in such filing.
 
Item 9.01 Financial Statements and Exhibits.
 
(d) Exhibits

Exhibit No.
 
Description
 
 
 
 
 

SIGNATURES
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
Date: March 12, 2020
 
 
FOAMIX PHARMACEUTICALS LTD.
 
 
 
 
 
By:
/s/ Mutya Harsch
 
 
 
Mutya Harsch
 
 
 
Chief Legal Officer
 
 

 


Foamix Pharmaceuticals (NASDAQ:FOMX)
Historical Stock Chart
From Oct 2024 to Nov 2024 Click Here for more Foamix Pharmaceuticals Charts.
Foamix Pharmaceuticals (NASDAQ:FOMX)
Historical Stock Chart
From Nov 2023 to Nov 2024 Click Here for more Foamix Pharmaceuticals Charts.